Asenapine

Results: 25



#Item
11U.S. Food and Drug Administration  Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. It was current when produced, but is no longer maintained and may

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. It was current when produced, but is no longer maintained and may

Add to Reading List

Source URL: www.fda.gov

Language: English
12Bulletin #852  December 20, 2012 NBPDP FORMULARY UPDATE This update to the New Brunswick Prescription Drug Program (NBPDP) Formulary is effective

Bulletin #852 December 20, 2012 NBPDP FORMULARY UPDATE This update to the New Brunswick Prescription Drug Program (NBPDP) Formulary is effective

Add to Reading List

Source URL: www.gnb.ca

Language: English - Date: 2012-12-20 13:00:13
13HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ® SAPHRIS (asenapine) safely and effectively. See full prescribing information for SAPHRIS. SAPHRIS (asenapine) sub

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ® SAPHRIS (asenapine) safely and effectively. See full prescribing information for SAPHRIS. SAPHRIS (asenapine) sub

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2011-08-11 15:17:32
14DEPARTMENT OF HEALTH & HUMAN SERVICES  Public Health Service Food and Drug Administration Silver Spring, MD 20993

DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993

Add to Reading List

Source URL: www.fda.gov

Language: English
15U.S. Food and Drug Administration  Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. It was current when produced, but is no longer maintained and may

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. It was current when produced, but is no longer maintained and may

Add to Reading List

Source URL: www.fda.gov

Language: English
16U.S. Food and Drug Administration  Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. It was current when produced, but is no longer maintained and may

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. It was current when produced, but is no longer maintained and may

Add to Reading List

Source URL: www.fda.gov

Language: English
17U.S. Food and Drug Administration  Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. It was current when produced, but is no longer maintained and may

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. It was current when produced, but is no longer maintained and may

Add to Reading List

Source URL: www.fda.gov

Language: English
18Questions to the PDAC – DRAFT-

Questions to the PDAC – DRAFT-

Add to Reading List

Source URL: www.fda.gov

Language: English
19Questions to the PDAC – DRAFT-

Questions to the PDAC – DRAFT-

Add to Reading List

Source URL: www.fda.gov

Language: English
20HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SAPHRIS (asenapine) safely and effectively. See full prescribing information for SAPHRIS. ®

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SAPHRIS (asenapine) safely and effectively. See full prescribing information for SAPHRIS. ®

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2013-03-26 13:25:17